Julia E. Lefler
Medical University of South Carolina
4 Papers
9 Citations
Julia E. Lefler is an academic researcher from Medical University of South Carolina. The author has contributed to research in topics: Stromal cell & Tumor microenvironment. The author has an hindex of 2, co-authored 4 publications. Previous affiliations of Julia E. Lefler include New York University.
Chat about Author
Papers
Defining the Tumor Microenvironment by Integration of Immunohistochemistry and Extracellular Matrix Targeted Imaging Mass Spectrometry.
Denys Rujchanarong,Julia E. Lefler,Janet E. Saunders,Sarah Pippin,Laura Spruill,Jennifer R. Bethard,Lauren E. Ball,Anand Mehta,Richard R. Drake,Michael C. Ostrowski,Peggi M. Angel +10 more
TL;DR: In this paper, a targeted approach for investigating collagen and other extracellular matrix proteins from formalin-fixed, paraffin-embedded (FFPE) tissues was proposed.
20
PTEN in the Stroma.
TL;DR: In this review, the evidence for PTEN function in different TME cell compartments, the mechanisms governing PTEN inactivation, and the downstream pathways regulated by PTEN that are critical for intracellular communication are covered.
Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis.
Imran Khan,Imran Khan,Catherine MarElia-Bennet,Catherine MarElia-Bennet,Julia E. Lefler,Julia E. Lefler,Mariyam Zuberi,Mariyam Zuberi,Eric Denbaum,Akiko Koide,Dean M. Connor,Ann-Marie Broome,Thierry Pécot,Thierry Pécot,Cynthia J. Timmers,Cynthia J. Timmers,Michael C. Ostrowski,Michael C. Ostrowski,Shohei Koide,John P. O'Bryan,John P. O'Bryan +20 more
TL;DR: In this paper, the α4-α5 interface of RAS was used to inhibit PDAC development using an immunocompetent orthotopic mouse model, and the results suggest that targeting the #x3B1;4-#x3b1;5 allosteric site of KRAS may represent a viable therapeutic approach for inhibiting KRAS-mutant pancreatic tumours.
12
Redundant function of Ets1 and Ets2 in regulating M-phase progression in post-natal angiogenesis
Sankha Ghosh,Catherine B. MarElia-Bennett,Blake E. Hildreth,Blake E. Hildreth,Julia E. Lefler,S. Sharma,S. Sharma,Michael C. Ostrowski,Michael C. Ostrowski +8 more
TL;DR: It is demonstrated that deletion of Ets1 and Ets2 in endothelial cells inhibits angiogenesis by altering cell cycle progression and decreasing cell survival.